Such pluripotent stem cells are characterized by their bidirectional developmental potential (contributing to both embryonic and extraembryonic lineages) and their strong induction of the MuERV-L (MERVL) endogenous retroviruses (ERVs), both of which are features of totipotent two-cell (2C) blastomeres. The low efficiency in generating bipotential ESCs reflects the existence of multiple cellular and molecular impediments that restrict the pluripotent cell fate potential.
RATIONALE:
We identified miR-34a micro-RNA (miRNA) as a potent regulator that restricts the cell fate potential of ESCs and iPSCs to a pluripotent state. miR-34a −/− pluripotent stem cells exhibit a bidirectional cell fate potential, generating both embryonic and extraembryonic cell lineages in multiple functional assays. Hence, the miR-34a −/− pluripotent stem cells provide a powerful experimental system to dissect the molecular mechanisms that restrict cell fate potential in ESCs and iPSCs.
RESULTS: miR-34a −/− ESCs and iPSCs exhibited an expanded cell fate potential, generating both embryonic and extraembryonic lineages in teratomas, embryoid bodies, and chimeric embryos. In particular, a single miR-34a −/− ESC injected into a recipient morula could yield progenies in both inner cell mass (ICM) and trophectoderm. Expression profiling studies comparing wild-type and miR-34a −/− pluripotent stem cells revealed a strong and specific induction of the MERVL ERVs, together with many MERVL-proximal genes, in miR-34a
ESCs and iPSCs. Whereas wild-type ESCs and iPSCs almost exclusively expressed Oct4, miR-34a
ESCs and iPSCs were heterogeneous, containing mutually exclusive populations with either Oct4 expression or MERVL induction. Because MERVL is a specific and highly expressed molecular marker for totipotent 2C blastomeres and for bipotential ESCs, we investigated the mechanism by which miR-34a regulates MERVL expression. We demonstrated that MERVL induction in miR-34a-deficient pluripotent stem cells is regulated at the transcriptional level, at least in part because of an increase of the transcription factor Gata2, a direct target of miR-34a. Knockdown of gata2 in miR-34a-deficient pluripotent stem cells phenocopied miR-34a overexpression, not only down-regulating the expression of MERVL but also abolishing their bipotential cell fate. Thus, miR-34a restricts cell fate potential and represses MERVL induction in pluripotent stem cells, at least in part through down-regulation of Gata2.
CONCLUSION:
We have identified miR-34a as a noncoding RNA that restricts the cell fate potential of ESCs and iPSCs to a pluripotent state. The miR-34a/gata2/MERVL axis plays an essential role in modulating the transition between pluripotent stem cells and bipotential stem cells in culture. Thus, an intricate network of protein-coding genes, noncoding RNAs, and endogenous retroviruses could act cooperatively to define cell fate plasticity and developmental potential in pluripotent stem cells.
M
ouse embryonic stem cells (ESCs), derived from the inner cell mass (ICM) of blastocysts, and induced pluripotent stem cells (iPSCs), generated by somatic reprogramming, are classically defined as pluripotent stem cells (1) (2) (3) . As a population, ESCs and iPSCs contribute to all embryonic cell types in vitro and in vivo, but they rarely contribute to extraembryonic cell lineages in the placenta and yolk sac (4) . This restricted pluripotent potential contrasts with that of totipotent mouse zygotes and two-cell (2C) blastomeres, which give rise to both embryonic and extraembryonic cell lineages during normal development (5, 6) . Rare pluripotent stem cell populations with expanded cell fate potential have been identified in culture as a result of genetic alterations, derivation methods, culture conditions, or enrichment with specific molecular markers (7) (8) (9) (10) . Such pluripotent stem cells exhibit bidirectional cell fate potential, contributing to both embryonic and extraembryonic lineages in vitro and in vivo (7) (8) (9) (10) .
A key molecular signature shared by ESCs and iPSCs with bidirectional potential is the strong induction of the MuERV-L (MERVL) family of murine endogenous retroviruses (ERVs), which only occurs in totipotent 2C blastomeres during normal mouse pre-implantation development (7, 9) . These studies suggest that rare, cultured ESCs and iPSCs could acquire features of cell fate plasticity reminiscent of early blastomeres; however, little is known about the molecular barriers restricting ESC or iPSC developmental potential to a pluripotent cell state. Here, we identified the miR-34a microRNA (miRNA) as a noncoding regulator that restricts pluripotent cell fate potential in cultured ESCs and iPSCs, showing that deficiency of this miRNA in pluripotent stem cells yields bidirectional cell fate potential and MERVL induction.
Expanded cell fate potential of miR-34a
−/− pluripotent stem cells miRNAs are a class of small, regulatory noncoding RNAs that regulate gene expression posttranscriptionally through a combined mechanism of mRNA degradation and translational repression (11, 12) . These small noncoding RNAs have been implicated in numerous cellular processes in development and disease, and they have become increasingly recognized as key regulators of cell fate specification in diverse developmental systems, including pluripotent stem cells (13) (14) (15) (16) .
Initially identified as bona fide p53 transcriptional targets in tumor suppression (17) (18) (19) (20) (21) (22) , the miR-34 miRNAs (miR-34a, miR-34b, and miR-34c) were previously characterized as key barriers to somatic reprogramming (17) . miR-34a deficiency significantly enhanced the efficiency of iPSC generation, producing iPSCs with normal self-renewal and pluripotency ( fig. S1 , A to C) (17) . However, teratomas generated from miR-34a −/− iPSCs, but not those from wild-type iPSCs, contained cellular features reminiscent of trophoblast giant cells in the placenta, characterized by PL-1 (placental lactogen 1) expression, large cell volume, enlarged nuclei, and close proximity to internal hemorrhages (Fig. 1A) . In ESCs, miR-34a accounted for the majority of miR-34 family miRNA expression ( fig. S1D ). Similar to miR-34a −/− iPSCs, miR-34a −/− ESCs also generated teratomas that contained not only derivatives of the three germ layers ( fig. S1B ) but also features of extraembryonic placental lineages (Fig. 1A) . Consistently, miR-34a −/− teratomas exhibited induction of multiple trophectoderm markers (Fig. 1B and fig. S1E 1D and fig. S1F ), trophectoderm markers, extraembryonic endoderm markers, and trophoblast cell markers (23, (26) (27) (28) were strongly induced only in miR-34a −/− EBs (Fig. 1 , C and D, and fig. S1 , F and G). Using immunofluorescence staining, we confirmed that a significant percentage of miR-34a −/− EBs were Cdx2-positive and that these Cdx2-positive cells preferentially localized to the EB periphery ( Fig. 1C and fig. S1H ). Thus, upon EB differentiation, miR-34a −/− pluripotent stem cells exhibited expanded cell fate potential, generating cells with molecular features of both embryonic and extraembryonic lineages.
To define the cell fate potential of miR-34a
pluripotent stem cells in normal development, we traced the cell fate of their progenies in chimeric blastocysts. Initially, four green fluorescent protein (GFP)-labeled wild-type or miR-34a
mouse ESCs were microinjected into each C57BL/ 6N recipient mouse morula to generate chimeric blastocysts ( Fig. 2A) . Although wild-type ESCs exclusively gave rise to cells localized to the ICM ( Fig. 2A and table S1 ), miR-34a −/− ESC progenies localized to both the ICM and trophectoderm iñ 60% of chimeric blastocysts ( Fig. 2A and table  S1 ). This expanded cell fate potential is unlikely to be due to extraembryonic contamination during miR-34a −/− ESC derivation, because miR-34a
iPSCs derived from mouse embryonic fibroblasts (MEFs) phenocopied miR-34a −/− ESCs in this expanded developmental potential ( fig. S1I ). When aggregated with recipient C57BL/6J morulae, miR-34a −/− iPSC and ESC progenies colonized both ICM and trophectoderm in~25% of chimeric blastocysts, whereas progenies from passage-and littermate-controlled wild-type ESCs and iPSCs exclusively contributed to the ICM ( Fig. 2A and fig. S1I ).
Given the expanded cell fate potential in both miR-34a −/− ESCs and miR-34a −/− iPSCs, we compared the miRNA profiles between miR-34a teratomas similarly induced the expression of pax6 (an ectoderm marker), brachyury (a mesoderm marker), and foxa2 (an endoderm marker). Teratomas were generated from two independent pairs of passage-and littermatecontrolled wild-type and miR-34a −/− ESC lines. Data are means ± SD, n = 3.
(C) miR-34a −/− EBs yield a greater percentage of Cdx2-positive EBs and stronger Cdx2 expression, with the Cdx2 induction primarily in cells at the periphery. Scale bars, 100 mm. Data are means ± SD, n = 5 to 7 randomly selected 10× fields. (D) miR-34a −/− EBs showed an increase in the expression of trophectoderm (TE) markers cdx2 and elf5. In contrast, wild-type and miR-34a −/− EBs similarly induced the expression of pax6, brachyury, and foxa2. EBs were generated from three independent pairs of passage-and littermate-controlled wild-type and miR-34a −/− ESC lines. Data are means ± SEM, n = 3. *P < 0.05, **P < 0.01 (two-tailed Student t test); n.s., not significant.
pluripotent stem cells and their wild-type controls. We demonstrated that miR-34a was the only miRNA strongly depleted in both miR-34a (table S1 ), yet 30% chimeric embryos have at least two different extraembryonic cell types derived from the miR-34a −/− ESCs.
comparison, miR-34a −/− ESCs contributed to both embryonic and extraembryonic cell lineages in E9.5 (embryonic day 9.5), E12.5, and E14.5 chimeric embryos ( 
MERVL induction in miR-34a −/− ESCs and iPSCs
To investigate the molecular basis for the bidirectional potential of miR-34a −/− pluripotent stem cells, we compared the transcriptomes of wild-type and miR-34a −/− iPSCs with the use of RNA sequencing (RNA-seq). We compared the abundance of all annotated transcripts between wild-type and miR-34a −/− iPSCs, including proteincoding genes, long noncoding RNAs (lncRNAs), pseudogenes, antisense transcripts, and retrotransposons ( Fig. 3A) , using 100-base pair (bp) pairedend RNA-seq data. Given the repetitive nature of retrotransposons, we used both uniquely and nonuniquely mapped reads to quantify retrotransposon expression at the family level; we assigned each multimapped read to the best possible alignment and subsequently summed the reads from all the retrotransposon loci to obtain family-level expression estimates (see supplementary materials). Some of the most highly expressed and differentially regulated transcripts in miR-34a
iPSCs were transcribed from the MERVL family of ERVs (Fig. 3A and fig. S2A ), which is also MERVL elements located within introns, either as solo LTRs (e.g., the MT2_Mm element in intron 13 of abcb5) or as complete ERV elements (e.g., the MERVL element in intron 5 of tmem132c), also act as alternative promoters to drive the expression of truncated gene isoforms that contain only the downstream exons. Given the repetitive nature of MERVL LTRs, we cannot definitively determine which LTR of the full-length MERVL element acts as the alternative promoter for its proximal gene using the RNA-seq data. (C) miR-34a overexpression in miR34a −/− iPSCs using a MSCV (murine stem cell virus) retroviral vector significantly suppressed the level of MERVL and the MERVL-zfp352 chimeric transcript in real-time PCR analysis. In comparison, miR-34a overexpression caused no alteration in the level of IAP retrotransposon. One pair of passage-and littermate-controlled wild-type and miR-34a
iPSCs was examined. In (B) and (C), data are means ± SD, n = 3; *P < 0.05, **P < 0.01, ***P < 0.001 (two-tailed Student t test). highly induced in totipotent 2C blastomeres and previously characterized bipotential ESCs (7, 9, 29, 30) . In fact, transcripts from MERVL ERVs constitute nearly 3% of the transcriptome in 2C blastomeres (29) (30) (31) . Retrotransposon induction in miR-34a −/− ESCs and iPSCs was largely specific to the MERVL family, as this induction was not observed in other families, such as intracisternal A-particle (IAP), long interspersed nuclear elements (LINEs), and short interspersed nuclear elements (SINEs) (Fig. 3, A and B S2 , B and C). The MERVL ERVs have been retained throughout mammalian evolution, with independent expansion in the murine and primate genomes (32) . There are 2502 MERVL loci in the C57B6/J mouse genome (32), 26% of which encode elements with an intact retroviral structure, comprising 5′ and 3′ LTRs flanking the coding sequences for gag, pol, and dUTPase, but lacking env-like open reading frames (ORFs) (Fig. 3C) . Another 32% of MERVL loci exhibit truncated retroviral structure, missing one or both LTRs (Fig. 3C) . The remaining 41% of MERVL loci have undergone homologous recombination, yielding solo LTRs (MT2_Mm) with varying degrees of sequence degeneration (Fig. 3C) . We obtained bioinformatic estimates of locus-specific MERVL expression in wild-type and miR-34a −/− iPSCs using our RNA-seq data (table S3 and supplementary materials) . Notably, definitive evidence for MERVL induction in miR-34a −/− iPSCs was observed predominantly for loci harboring MERVLs with a complete retroviral structure, but not for those with truncated structure (Fig.  3D, fig. S2D , and table S3). A fraction of MT2_Mm solo LTRs, along with a few elements from the highly related MERVL solo LTRs (MT2B, MT2B1, MT2B2, and MT2A), also exhibited a similar induction ( fig. S2A and table S3 ). These findings suggest that an intact LTR, which likely contains the retrotransposon promoter sequences, is likely required for the induction of a MERVL locus. Approximately 300 MERVL loci still encode intact Gag viral protein (7) . We observed a significant increase in MERVL-Gag expression and in the percentage of MERVL-Gag-positive cells in miR-34a −/− pluripotent stem cells (Fig. 3, E and F). Intriguingly, miR-34a −/− ESCs and iPSCs were both heterogeneous populations, containing~12% and~20% MERVL-Gag-positive cells, respectively, in otherwise Oct4-positive colonies (Fig. 3, E and F, and fig. S2, E and F correlates with the induction of many genes that harbor either a proximal upstream MERVL or an intronic MERVL on the same strand ( Fig. 4A and  fig. S3D ). In some cases, MERVL or related loci, particularly solo LTRs, act as alternative promoters, generating chimeric transcripts of proximal genes that differ in 5′ untranslated regions (5′ UTRs) and/or ORFs (Fig. 4B, fig. S3 , E and F, and tables S4 and S5). These MERVL-gene chimeric transcripts can be unambiguously identified by their corresponding splice junctions from the RNA-seq data (table S5) . Using real-time PCR analyses, we validated the induction of multiple MERVL-proximal genes in miR-34a −/− ESCs and iPSCs, including zfp352, cml2, p4ha2, tcstv1, and tcstv3 (harboring a proximal upstream MERVL element), as well as abcb5, tmem132c, and chit1 (harboring an intronic MERVL element) (Fig. 4B  and fig. S3 , E to G). The induction level of
MERVL-gene isoforms varied among individual miR-34a
−/− iPSC colonies but appeared to correlate with the extent of MERVL induction ( fig. S3G ). Consistent with these observations, miR-34a overexpression in miR-34a −/− iPSCs not only decreased MERVL expression but also reduced the level of the MERVL-driven chimeric transcript, such as zfp352 (Fig. 4C) . Given the technical difficulty of mapping repetitive RNA-seq reads, we repeated our analysis using 150-bp pair-ended RNA-seq data to gain confidence in the accuracy of our retrotransposon mapping. Our RNA-seq analysis using longer sequence reads confirmed the induction of MERVL ERVs and MERVL-proximal genes in miR-34a −/− iPSCs ( fig. S4, A and B) .
Transcriptional activation of MERVL in miR-34a −/− ESCs and iPSCs
Given the correlation between MERVL induction and bipotential pluripotent stem cells (7, 9, 34) (Fig. 3, A and B) , the molecular pathway that mediates miR-34a-dependent MERVL repression could also regulate miR-34a-dependent restriction of pluripotent potential. To determine the key MERVL sequences required for its induction in miR-34a −/− pluripotent stem cells, we transfected wild-type and miR-34a −/− ESCs with a MERVL 1-1000 -Luc (luciferase) reporter containing the full-length LTR (MT2_Mm) and a portion of the gag sequence as the promoter (34) . This reporter showed elevated luciferase activity in miR-34a −/− ESCs relative to wild-type ESCs, faithfully recapitulating the endogenous MERVL induction (Fig. 5A ). The LTR sequence was both necessary and sufficient for the MERVL 1-1000 -Luc reporter activity in miR-34a −/− ESCs (Fig. 5A) ; furthermore, a minimal 250-bp fragment, MERVL 125-375 , containing a predicted TATA box, was sufficient to drive strong luciferase activity specifically in miR-34a −/− ESCs (Fig. 5A) . The MERVL fragment is conserved among the most highly induced MERVL loci in miR-34a −/− iPSCs ( fig.   S5A ), suggesting a sequence-dependent transcriptional mechanism for MERVL induction. Consistent with this inference, miR-34a −/− ESCs also exhibited H3K4Me3 (trimethylated histone 3 Lys 4 ) enrichment near the LTR of MERVL ERVs and near the MERVL LTR proximal to tcstv1, but not near other ERVs such as IAP or Mus musculus endogenous retrovirus subtype K10C (MMERVK10C) (Fig. 5B) . Thus, MERVL loci are specifically enriched for active transcription machinery in miR-34a −/− pluripotent stem cells.
Gata2 mediates MERVL induction in miR-34a −/− ESCs and iPSCs
The MERVL 125-375 fragment likely contains cisregulatory elements necessary and sufficient to enable MERVL induction in miR-34a −/− ESCs and iPSCs. We failed to detect any significant sequence complementarity between miR-34a (pri-, pre-, or mature miRNA sequences) and the MERVL 125-375 sequence, thus precluding a direct, RNA base pairing-dependent repression mechanism. We bioinformatically predicted 70 candidate transcription factors that could potentially bind within Data are means ± SD, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001 (two-tailed Student t test). (D) Mutating all three predicted miR-34a binding sites within the Luc-gata2-3UTR luciferase reporter completely abolishes miR-34a-dependent repression. Data are means ± SD, n = 2. (E) RNAimediated gata2 knockdown in miR-34a −/− iPSCs abolishes induction of the TE marker cdx2 during EB differentiation but has no effect on induction of ectoderm (pax6), mesoderm (brachyury), or endoderm (foxa2) markers. Data are means ± SD, n = 3. (F) miR-34a overexpression in miR-34a −/− iPSCs using MSCV retroviral vectors significantly suppresses the induction of the TE marker cdx2 upon EB differentiation. The induction of ectoderm (pax6), mesoderm (brachyury), and endoderm (foxa2) markers is not affected. Data are means ± SD, n = 3. In (E) and (F), results shown are representative of two independent experiments using the same miR-34a −/− iPSC line. (G) The expanded cell fate potential of miR-34a −/− iPSCs is restricted by gata2 knockdown in chimeric assays. Left: Four GFP-labeled iPSCs were injected into each recipient morula to generate chimeric blastocysts, and their contributions to the ICM and the trophectoderm were determined by the localization of GFP-positive iPSC progenies. Right: Whereas 50% of chimeric blastocysts generated from control infected miR-34a −/− iPSCs contained an iPSC contribution to both the ICM and the TE (white arrows) (n = 7/14), miR-34a −/− iPSCs with gata2 knockdown lacked this expanded cell fate potential (n = 0/13) and primarily contributed to the ICM (n = 11/13).
Red dashes mark the boundary between the ICM and the blastocoel. Scale bars, 20 mm. *P < 0.05, ***P < 0.001 (two-tailed Student t test). MERVL 125-375 , among which only GATA-binding protein 2 (Gata2) exhibits an expression pattern similar to that of MERVL during early preimplantation development, as confirmed by both our real-time PCR analyses and previously reported RNA-seq data [ fig. S5B , based on data from previous studies (35, 36) ].
Aligning the LTR sequences from 18 MERVL loci that were strongly induced in miR-34a −/− iPSCs, we found that all of the loci harbored at least two putative gata2 binding sites, with most loci harboring three binding sites ( fig. S5A ). Mutating the two best-conserved putative Gata2 binding sites (BS1 and BS3) within the MERVL 125-375 -Luc reporter significantly reduced its activity in miR-34a −/− pluripotent stem cells (Fig. 5C ). Similarly, gata2 knockdown in miR-34a −/− pluripotent stem cells effectively abolished the induction of MERVL and MERVL-proximal genes (zfp352, tmem132c, and chit1) (Fig. 5D and fig. S5C ) and significantly decreased MERVL and cdx2 induction in the subsequent teratoma analyses ( fig. S5D ). gata2 knockdown in miR-34a −/− iPSCs also reduced H3K4Me3 deposition on MERVL and the MERVL-proximal gene tcstv1, suggesting a decrease in active transcriptional machinery on MERVL loci (Fig. 5E ). Finally, using chromatin immunoprecipitation (ChIP), we demonstrated specific Gata2 binding to the MERVL LTR, but not to the MERVL internal regions or other ERVs (such as IAP or MMERVK10C), in Gata2-overexpressing miR-34a −/− pluripotent stem cells (Fig. 5F ). Additionally, Gata2 binding at the MERVL LTR was greater in miR-34a −/− pluripotent stem cells than that in wild-type controls ( fig. S5E ). Together, our data suggest that Gata2 plays an essential role in directly promoting the induction of MERVL ERVs and MERVL-proximal genes in miR-34a −/− pluripotent stem cells. Previous studies also reported the importance of epigenetic regulation in MERVL induction (34, 37, 38) . However, no obvious alterations were detected between wild-type and miR-34a suggests that a global increase of H3K4Me1 had no effect on the direct MERVL silencing by miR-34a. Hence, none of the tested epigenetic mechanisms appeared to be essential for miR-34a-mediated MERVL repression.
miR-34a directly represses Gata2
Gata2 plays an essential role in mediating MERVL activation in miR-34a −/− pluripotent stem cells (Fig. 5D) and also emerges as a strong candidate for a direct miR-34a target (Fig. 6A) . gata2 harbors three predicted miR-34a binding sites (39) , two of which (site 1 and site 3) were predictions with a perfect seed match and/or a strong 3′ complementary base pairing (Fig. 6A) . Consistent with this hypothesis, Gata2 exhibited miR-34a-dependent regulation in pluripotent stem cells; gata2 protein and mRNA levels were increased in miR-34a −/− pluripotent stem cells and reduced upon ectopic miR-34a overexpression (Fig. 6 , B and C). Additionally, a luciferase reporter containing a fragment of the gata2 gene with all three predicted miR-34a binding sites exhibited miR-34a-dependent repression, and mutating all three predicted miR-34a binding sites in this reporter abolished this regulation (Fig. 6D) . Consistent with gata2 derepression in miR-34a
ESCs and iPSCs, a number of previously validated Gata2 targets, including dab2, cd34, and gata1 (40-42), exhibited Gata2-dependent upregulation in miR-34a −/− iPSCs ( fig. S6, A and   B ). Together, these findings show that gata2 is likely a direct miR-34a target in ESCs and iPSCs, thereby mediating MERVL expression transcriptionally. Knockdown of gata2 using RNA interference (RNAi) in miR-34a −/− iPSCs phenocopied miR-34a
overexpression, not only down-regulating the expression of MERVL and MERVL-proximal genes (Fig. 4C, Fig. 5D, and fig. S5C ) but also abolishing their bidirectional developmental potential (Fig.  6 , E to G). In an EB differentiation assay, gata2 knockdown or miR-34a overexpression in miR-34a
pluripotent stem cells impaired the induction of the trophectoderm marker cdx2, without affecting the induction of the markers for all three germ layers (Fig. 6 , E and F). More important, although the control infected miR-34a −/− iPSCs contributed to both ICM and trophectoderm in 50% of the chimeric blastocysts (n = 7/14, Fig. 6G and table S1), miR-34a −/− iPSCs with gata2 knockdown lost this expanded cell fate potential and failed to differentiate into both embryonic and extraembryonic lineages (n = 0/13, Fig. 6G and table S1 ). Consistent with these findings, late-passage miR-34a
ESCs that had lost MERVL induction and bidirectional potential also exhibited a decrease in gata2 level through an unknown mechanism ( fig.  S2 , B and C, and fig. S6C ). Hence, miR-34a is a noncoding RNA that restricts the cell fate potential of ESCs and iPSCs to a pluripotent state. Whereas multiple miR-34a targets are likely to act collectively to restrict cell fate potential and repress MERVL expression in pluripotent stem cells, the miR-34a/Gata2 axis clearly plays an essential role in this process (Fig. 7) .
Discussion
Mouse zygotes and early blastomeres possess a totipotent cell fate potential, generating both embryonic and extraembryonic cell types during normal development (5, 6). As pre-implantation development progresses, this totipotent or totipotent-like cell fate potential is gradually restricted (43, 44) . By the late blastocyst stage, the separation of trophectoderm (which develops into the placenta), epiblast (which forms the embryo proper), and primitive endoderm (which develops into the yolk sac) signals the completion of the first cell fate specification event in mammalian development (45) . This cell fate specification commits the developmental potential of cells to either embryonic or extraembryonic lineages (45) . ESCs and iPSCs in culture faithfully recapitulate the developmentally restricted, pluripotent cell fate potential of the epiblast, as they efficiently contribute to all embryonic cell lineages in vivo, but rarely to extraembryonic lineages (4). Experimentally, stem cells with bidirectional developmental potential can be obtained, albeit with low efficiency, using somatic nuclear transfer, genetic modifications, or specific enrichment, culture, or derivation procedures in ESC or iPSC cultures (7-10, 23, 46) . This low efficiency in generating bipotential ESCs reflects the existence of cellular and molecular impediments that restrict the pluripotent cell fate potential. miR-34a plays an important role in maintaining cell fate identity in multiple contexts, as it restricts the pluripotent cell fate potential of ESCs and iPSCs and acts as a barrier to somatic reprogramming (17) . miR-34a is a noncoding RNA whose deficiency in ESCs or iPSCs generates a substantial fraction of cells with bidirectional developmental potential and strongly induces the expression of MERVL ERVs. Unlike previously reported bipotential pluripotent stem cells, miR-34a −/− ESCs and iPSCs are more stable in maintaining their cell fate potential and contain a high percentage of MERVL-positive cells in culture (7, 9) . MERVL induction in miR-34a −/− ESCs and iPSCs could simply be an indicator of a unique 2C-like transcriptional and epigenetic state. An interesting parallel can be drawn to human ESCs, wherein the levels of specific retrotransposon families indicate a dynamic population of naïve-state pluripotency (47, 48) . Alternatively, MERVL could functionally contribute to the establishment and/or maintenance of the 2C-like cell fate potential, in part by rewiring gene regulatory networks to induce many 2C-specific, MERVLproximal genes (Fig. 4 , A and B) (7, 9) . Although most MERVL-proximal genes are poorly characterized so far, we found a few genes that mediate important cellular events in pre-implantation development, including Hnf4a, which regulates visceral endoderm differentiation (49) , and Usp17lc (Dub-2), which affects the development of the trophectoderm (50) . Taken together, these findings suggest the possibility that ERVs, while traditionally viewed as evolutionary remnants of invading foreign DNA sequences, could have important yet unrecognized developmental functions. Although miR-34a deficiency expands cell fate potential in pluripotent stem cells, miR-34a −/− mice undergo normal pre-implantation development under laboratory conditions (17, 51) . Interestingly, miR-34a is induced at the 4C to 8C transition during pre-implantation development ( fig. S5B ), precisely coinciding with the initiation of MERVL silencing (29-31, 52) . We compared the levels of MERVL-Gag protein, MERVL transcripts, and MERVL-proximal gene expression in wild-type and miR-34a −/− preimplantation embryos, but observed no obvious differences ( fig. S7, A and B) . It is conceivable that the molecular network mediating MERVL silencing in pre-implantation embryos is highly redundant. The six miR-34 family miRNAs could act redundantly to repress MERVL expression, and miR-34-independent pathways could also act in parallel to ensure rapid and efficient MERVL silencing in vivo. In addition, it is important to recognize the incomplete penetrance of the expanded cell fate potential in miR-34a −/− ESCs and iPSCs (Fig. 2, A and B). Pluripotent stem cell culture provides a highly sensitive experimental system that enables detection of altered cell fate potential at the single-cell level, whereas a partially altered cell fate potential in early blastomeres could be tolerated in mouse pre-implantation embryos because of their unusually robust cell fate plasticity (6, 53) . Our studies identified Gata2 as an important miR-34a target that plays an essential role in mediating the MERVL induction and the bidirectional cell fate potential of pluripotent stem cells. In our studies, Gata2 was necessary but not sufficient to promote MERVL induction in pluripotent stem cells. Gata2 knockdown in miR-34a −/− ESCs abolished MERVL induction (Fig. 5D and  fig. S5C ), yet Gata2 overexpression in wild-type ESCs failed to induce MERVL expression ( fig.  S8A) (Fig. 7) . miR-34a deficiency increases Gata2-dependent transcription of MERVL endogenous retroviruses, shifting the equilibrium to enable more cells to acquire a bipotential cell fate (Fig. 7) . Our findings indicate that an intricate network of protein-coding genes, miRNAs, and retrotransposons act cooperatively to restrict cell fate plasticity and to define the pluripotent state of ESCs and iPSCs. Furthermore, these observations raise the tantalizing possibility of establishing in vitro conditions for culturing bipotential pluripotent stem cells to explore the molecular basis for totipotent developmental potential.
Materials and methods

Derivation of ESCs and generation of iPSCs
For ESC derivation, uteri containing E3.5 wildtype or miR-34a −/− embryos were isolated from timed pregnancies and transferred individually to a 12-well plate with irradiated MEF (mouse embryonic fibroblast) feeders. After 5 days of incubation, embryo outgrowths were separated from trophectoderm, individually picked, and expanded in mouse ES medium. For iPSC generation, wildtype and miR-34a −/− primary MEFs were isolated from littermate-controlled E13.5 wild-type and miR-34a −/− embryos, infected with retroviruses generated by pMX retroviral vectors that encode mouse Oct4, Sox2, and Klf4, and cultured on irradiated MEF feeder in ES medium. Subsequently, single iPSC-like colonies were individually picked and expanded on irradiated MEF feeders to establish stable lines. Cell lines used for in vivo experiments were validated free from microplasma contamination by PCR.
RNA-seq data analysis
RNA-seq reads were mapped to the GRCm38 (mm10) reference genome with TopHat to quantify gene and retrotransposon expression levels. MERVL-gene junctions were defined as those junctions, identified by TopHat, which overlap on one side with an annotated Ensembl gene (including protein-coding genes, long ncRNAs, pseudogenes, and antisense transcripts) and on the other side with an annotated element of MERVL (including complete, truncated, and solo LTR copies). We used EdgeR to test for differential expression between miR-34a −/− and wild-type iPSCs. We defined a gene as differentially expressed (DE) if it had an absolute log 2 fold change of at least 2 and a false discovery rate of less than 0.05. We performed the analysis using three data sets: HiSeq2000 100-bp paired-end data (100PE), NextSeq500 150-bp paired-end data (150PE), and a combined data set obtained by pooling the reads of the two (combined). This allowed us to quantify the effect of read length and sequencing depth on our analyses; the results are highly reproducible across the three data sets ( fig. S4 and tables S2 to S5).
Real-time PCR analysis for gene expression
RNA was isolated by Trizol extraction following manufacturer's instruction (Life Technologies, Cat. # 15596). cDNA was reverse-transcribed using iScript Advanced Reverse-Transcriptase (Bio-Rad, Cat. # 1725037). For single colony analysis, cDNA was prepared using a Single Cell-to-Ct qRT-PCR kit (Life Technologies, Cat. # 4458236). All realtime qPCR analyses were performed using SYBR FAST qPCR Master Mix (Kapa Biosystems, Cat. # KK4604). All primers used are listed in table S6. To detect MERVL expression, we designed four pairs of primers to amplify specific regions of MERVL (Fig. 2C) , which yielded similar results.
One pair of primers detecting the MERVL pol region was used for all other MERVL real-time PCR analyses.
Embryoid body (EB) differentiation
For EB differentiation, ESCs or iPSCs were plated in 10-cm petri dishes (150,000 cells/ml) in ES cell medium without leukemia inhibitory factor (LIF) and gently cultured on a rotator after removal of feeder cells. Samples were collected at days 0, 3, 6, and 9 after differentiation for real-time PCR analyses and for immunofluorescence staining.
Generation of chimeric blastocysts or chimeric mice from ESCs or iPSCs
To generate chimeric blastocysts by microinjection, we injected four ESCs or one ESC of the desired genotype into each E2.5 C57Bl/6N wildtype recipient morula, which was then cultured overnight to obtain chimeric blastocysts. To generate chimeric blastocysts by morula aggregation, we cultured one-cell embryos for 48 hours into morulae. After the removal of zona pellucida, morulae were aggregated with ESCs or iPSCs and then cultured overnight. To generate chimeric mice by microinjection, we injected 10 to 15 ESCs of the desired genotype into E3.5 recipient blastocyst embryos before implantation into the uterus of pseudo-pregnant mothers. Chimeric embryos were collected at E9.5, E12.5, and E14.5 for immunofluorescence and immunohistochemistry analyses.
Immunofluorescence and immunohistochemistry (IHC)
For immunofluorescence staining, cells, EBs, or embryo paraffin sections were fixed and blocked before incubation with primary antibodies (1:100, Cdx2, Abcam, Cat. # ab76541; 1:100), followed by secondary antibody incubation and DAPI staining. For IHC of teratomas and chimeric mouse embryos, tissue paraffin sections were incubated with primary antibodies against PL-1 (1:75, Santa Cruz Biotechnology, Cat. # sc-34713) or GFP (1: 100, Abcam, Cat. # ab38689).
